Results 21 to 30 of about 19,315 (197)

Clopidogrel versus ticagrelor in East Asian patients aged 75 years or older with acute coronary syndrome: observations from the GF-APT registry

Platelets, 2022
The benefits of potent antithrombotic therapy usually come at the expense of a higher risk of bleeding. The efficacy and safety of ticagrelor in elderly East Asian populations remains debated due to the concerns about the imbalance of ischemic and ...
Ziwei Xi, Zifeng Qiu, Jianan Li, Hong Qiu, Tingting Guo, Yong Wang, Jianfeng Zheng, Yanan Gao, Runlin Gao   +8 more
doaj   +1 more source

Fluorescence quenching-based immunological probe for ticagrelor monitoring

Frontiers in Bioengineering and Biotechnology, 2023
Introduction: Ticagrelor is extensively utilized for the treatment of acute coronary syndromes (ACS), but its platelet aggregation inhibitory effects can potentially result in tissue bleeding, posing a serious risk to patients’ lives.Methods: In this ...
Shengshuo Zhang, Shengshuo Zhang, Yueqing Cheng, Yujie Gao, Yujie Zou, Weiling Xiao, Tianyi Li, Mei Li, Bowen Yu, Jinhua Dong, Jinhua Dong   +10 more
doaj   +1 more source

Cost-effectiveness of Platelet Function-Guided Strategy with Clopidogrel or Ticagrelor [PDF]

, 2019
Some patients treated with dual antiplatelet therapy (DAPT) following acute coronary syndrome (ACS) can still exhibit heightened residual platelet reactivity (HRPR), which is potentially linked to adverse vascular outcomes.
Liudmila Buryachkovskaya, Nikita Lomakin, Victor Serebruany, Anna Rudakova   +3 more
core   +1 more source

Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA

, 2021
BACKGROUND Comparisons between ticagrelor and clopidogrel for the secondary prevention of stroke in CYP2C19 loss-of-function carriers have not been extensively performed.
Li, Hao, Li, Wei, Liu, Liping, Lin, Jinxi, CHANCE-2 Investigators, Jing, Jing, Zhao, Xingquan, Li, Zixiao, Feng, Yefang, Xie, Xuewei, Wang, Lihua, Zhuang, Xiabo, Niu, Siying, Johnston, S. Claiborne, Dong, Qiang, Bath, Philip M., Wang, Baojun, Wang, Yilong, Jiang, Yong, Xu, Jie, Chang, Liguo, Meng, Xia, Pan, Yuesong, Xu, Anding, Wang, Anxin, Zhao, Jinguo, Li, Guozhong, Wang, Yongjun, Man, Honghao   +28 more
core   +1 more source

Cost-effectiveness of ticagrelor and generic clopidogrel in patients with acute coronary syndrome in Switzerland [PDF]

, 2013
QUESTION UNDER STUDY The aim of this study was to evaluate the cost-effectiveness of ticagrelor and generic clopidogrel as add-on therapy to acetylsalicylic acid (ASA) in patients with acute coronary syndrome (ACS), from a Swiss perspective ...
David Gasche, Tanja Ulle, Greiner, Roger-Axel, Bernhard Meier, Meier, Bernhard, Gasche, David, Ulle, Tanja, Roger-Axel Greiner   +7 more
core   +1 more source

A Potential Mechanism of High-Dose Ticagrelor in Modulating Platelet Activity and Atherosclerosis Mediated by Thymic Stromal Lymphopoietin Receptor. [PDF]

PLoS ONE, 2015
Abnormal expression of thymic stromal lymphopoietin (TSLP) and its receptor (TSLPR) was found in patients with acute coronary syndrome. Ticagrelor, an oral platelet ADP P2Y12 receptor antagonist, is widely used in these patients.
Yi Mao, Yudong Peng, Qiutang Zeng, Longxian Cheng, Boyuan Wang, Xiaobo Mao, Kai Meng, Yuzhou Liu, Yitian Lian, Dazhu Li   +9 more
doaj   +1 more source

Ticagrelor reduces doxorubicin-induced pyroptosis of rat cardiomyocytes by targeting GSK-3β/caspase-1

Frontiers in Cardiovascular Medicine, 2023
Doxorubicin (Dox) is a widely used clinical drug whose cardiotoxicity cannot be ignored. Pyroptosis (inflammatory cell death) has gradually gained attention in the context of Dox-induced cardiotoxicity.
Shu-hui Wang, Meng-jin Sun, Si-yue Ding, Chun-li Liu, Jing-min Wang, Sheng-na Han, Xi Lin, Qian Li   +7 more
doaj   +1 more source

Successful Use of Recombinant Activated Factor VII to Reverse Ticagrelor-Induced Bleeding Risk: A Case Report

TH Open, 2018
Management of ticagrelor-associated bleeding is challenging, especially in neurosurgery. Platelet transfusion is inefficient and no antidote is currently available.
Anne Godier, Mélanie Dupont, Jean-Philippe Desilles, Caroline Le Guerinel, Guillaume Taylor, Mathilde Perrin, Anne-Céline Martin, Pascale Gaussem   +7 more
doaj   +1 more source

Efficacy and safety of standard and low dose ticagrelor versus clopidogrel in east AsianPatients with chronic total occlusion undergoing percutaneous coronary intervention: a single center retrospective study

BMC Cardiovascular Disorders, 2020
Background Patients with coronary chronic total occlusion (CTO) require effective antiplatelet therapy after percutaneous coronary intervention (PCI). Ticagrelor has more pronounced platelet inhibition than clopidogrel. However, the most appropriate dose
Yong Wang, Hong-wei Zhao, Cheng-fu Wang, Xiao-jiao Zhang, Jie Tao, Chun-sheng Cui, Qing-kun Meng, Yu Zhu, De-feng Luo, Ai-jie Hou, Bo Luan   +10 more
doaj   +1 more source

Ischemic and Bleeding Events of Ticagrelor Monotherapy in Korean Patients With and Without Diabetes Mellitus: Insights From the TICO Trial

Frontiers in Pharmacology, 2021
Background: Ticagrelor monotherapy after 3 months dual antiplatelet therapy (DAPT) with aspirin and ticagrelor can reduce bleeding without increasing ischemic events after percutaneous coronary intervention (PCI).
Kyeong Ho Yun, Jae Young Cho, Seung Yul Lee, Sang Jae Rhee, Byeong Keuk Kim, Myeong Ki Hong, Yangsoo Jang, Seok Kyu Oh, the TICO Investigators   +8 more
doaj   +1 more source